Romark Announces Initial Phase 3 Data Evaluating NT-300 Tablets for Mild to Moderate COVID-19
Romark announced initial results from a phase 3 trial evaluating NT-300 (nitazoxanide extended-release tablets, 300 mg) versus placebo as a treatment for mild or moderate…